Emergent BioSolutions Seeks Expanded BioThrax Label;

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Emergent BioSolutions Seeks Expanded BioThrax Label; Submits FDA Application for Post-Exposure Prophylaxis

ROCKVILLE, Md., Nov. 10, 2014 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS ) today announced that it has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking to expand the label of BioThrax ® (Anthrax Vaccine Adsorbed) to include a post-exposure prophylaxis (PEP) indication. BioThrax, the only FDA-licensed vaccine to prevent anthrax disease, is currently licensed for a pre-exposure prophylaxis indication only.

"This sBLA submission reflects years of collaboration between Emergent and the U.S. government to enhance the country's preparedness to meet immediate public health needs in the event of an anthrax attack. To date, these efforts have led to an enhanced route of administration, a streamlined vaccination schedule and an extended shelf life for BioThrax. The next milestones for this collaboration are an expanded product label to include PEP and an increase in our manufacturing capacity to a target of between 20-25 million doses per year," said Adam Havey, executive vice president and president biodefense division at Emergent BioSolutions.

The company made a Request for Priority Review Designation to potentially reduce the anticipated approval of this application to six months. The sBLA proposes to expand the BioThrax indication to include a post-exposure prophylaxis of disease resulting from suspected or confirmed Bacillus anthracis exposure when combined with the recommended course of antimicrobials in persons 18 through 65 years of age. The vaccination schedule consists of three doses of BioThrax administered at 0, 2, and 4 weeks post-exposure. This indication is supported by data from twelve non-clinical studies, three Phase 2/3 clinical trials, and a 2010 pre-Phase 3 Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting during which the regulatory pathway for licensure of anthrax vaccines for PEP was established.    
 
All studies supporting licensure were fully funded under contract number HHSO100200700037C provided by the Biomedical Advanced Research and Development Authority within the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services.

About Emergent BioSolutions

Emergent BioSolutions is a global specialty biopharmaceutical company seeking to protect and enhance life by offering specialized products to healthcare providers and governments to address medical needs and emerging health threats. Additional information about the company may be found at www.emergentbiosolutions.com . Follow us @emergentbiosolu.

About BioThrax

BioThrax is the only FDA-licensed vaccine for the prevention of anthrax disease. It is indicated for the active immunization of adults who are at high risk of exposure to anthrax. The safety and efficacy of BioThrax in a post-exposure setting have not been established. Individuals are not considered protected until they have completed the three-dose primary immunization series. Vaccination with BioThrax may not protect all individuals.

BioThrax is manufactured from a culture filtrate, made from a non-virulent strain of Bacillus anthracis. To date, Emergent has delivered over 66 million doses of BioThrax to the U.S. government and continues to deliver additional doses under active procurement contracts. Since 1998, over 12 million doses have been administered to more than 3 million military personnel. For full prescribing information, please visit http://www.biothrax.com/prescribinginformatio...rax_us.pdf .

BioThrax ® and any and all Emergent BioSolutions Inc. brand, product, service and feature names, logos and slogans are trademarks or registered trademarks of Emergent BioSolutions Inc. or its subsidiaries in the United States or other countries. All rights reserved.

Safe Harbor Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including statements regarding our strategy, future operations, prospects, plans and objectives of management, and any other statements containing the words "believes", "expects", "anticipates", "intends", "plans", "estimates" and similar expressions, are forward-looking statements. These forward-looking statements are based on our current intentions, beliefs and expectations regarding future events. We cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, we do not undertake to update any forward-looking statement to reflect new information, events or circumstances.

There are a number of important factors that could cause the company's actual results to differ materially from those indicated by such forward-looking statements, including the success of our ongoing and planned preclinical studies and clinical trials; the rate and degree of market acceptance and clinical utility of our products; the success of our ongoing and planned development programs; the timing of and our ability to obtain and maintain regulatory approvals for our product candidates; and our commercialization, marketing and manufacturing capabilities. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. Investors should consider this cautionary statement, as well as the risk factors identified in our periodic reports filed with the SEC, when evaluating our forward-looking statements.

Investor Contact: Robert G. Burrows Vice President, Investor Relations 301-795-1877 Media Contact: Tracey Schmitt Vice President, Global Public Affairs and Corporate Responsibility 301-795-1800

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Circuit Adds Gabe Klein as Microtransit Expansion Adviser

Updated Category News Views 29

Municipal mobility is a slow, political grind, not a shiny-app contest, and Circuit’s decision to add Gabe Klein to its board looks aimed squarely at that reality. The all-electric microtransit operator has brought aboard somebody who has worked inside the machinery of city government, federal transportation policy, electrification, venture investing, and transportation...

Continue Reading
Exiger's CEO Honored for Military Support Excellence

Updated Category News Views 256

Recognizing Civilian and Military Leadership When you hear "recognition in the military sector," it isn't just a pat on the back. It's a whole parade of brass hats and high-flyers giving their nods. So, November 10th wasn't just any regular day—Brandon Daniels, CEO of Exiger, gets a shiny, prestigious Five-Star Award for his "extraordinary support" of our military...

Continue Reading
Breakthrough T1D Gala Puts Research Progress First

Updated Category News Views 5

One person living without insulin after a cell-therapy trial is the detail that cuts through all the ballroom polish tonight. Breakthrough T1D's 53rd Annual New York City Promise Gala lands at the Plaza Hotel during National Diabetes Awareness Month, and it carries a message worth handling carefully: research can produce extraordinary outcomes, but one participant's...

Continue Reading
LRM Adds Two IND Studies Testing Injectable PDGF in Skin

Updated Category News Views 14

Under-eye medicine has a nasty habit of outrunning the evidence, which makes LRM's decision to put injectable rhPDGF-BB through more formal study worth watching. Lynch Regenerative Medicine has announced two FDA-accepted INDs for investigator-initiated clinical trials: one examining what the material does inside facial skin, the other testing it for infraorbital...

Continue Reading
COPD Support Program Targets a Costly Care Gap Today

Updated Category News Views 129

Breathing trouble gets shrugged off far too easily, and that casual mistake has consequences. World COPD Day puts chronic obstructive pulmonary disease back in view, with the American Lung Association emphasizing a free Lung Health Navigator program for people living with COPD, their caregivers and families. This is not flashy medicine or a miracle-cure pitch. It is...

Continue Reading
Historic China-Russia-US Summit Aims for Global Stability

Updated Category News Views 91

The Weight of History in Shenzhen When the big players decide to talk face-to-face, it's more than just a photo op. This week in Shenzhen, the leaders of China, Russia, and the United States are doing just that. And let me tell you, it's the kind of gathering that can either stabilize the gears of global politics or grease the wheels of tension. This chinwag isn't just...

Continue Reading
Anycubic Pushes Toward a Smoother 3D Printing Ecosystem

Updated Category News Views 51

Friction Is the Enemy in Consumer 3D Printing A printer that makes a beautiful object only after three failed attempts is not a consumer product; it is a weekend argument with plastic. That is the useful lens for Anycubic's Formnext 2026 showing in Frankfurt on November 18. The company is not merely rolling out FDM and resin machines at Booth F01 in Hall 12.0. It is...

Continue Reading
Oracle Takes AI to Construction's Messy Project Middle

Updated Category News Views 157

A stalled drywall inspection can wreck a schedule faster than any glossy AI pitch can repair it. That is the grimy, practical corner Oracle is aiming at with its latest Oracle Primavera Cloud upgrades: the daily hunt for answers, the repeated logging of familiar risks, and the finger-pointing that starts when a milestone is suddenly in danger. This is not a chatbot being...

Continue Reading
Abacus Global Faces Scrutiny Over Accounting Practices

Updated Category News Views 265

Storm Clouds Gather over Abacus Global Management If it ain't one thing, it's another—at least that's what folks holding the bag with Abacus Global (ABX) are thinking right now. News of a pending investigation has dropped like a lead balloon, and the air is thick with scrutiny over their financial dealings. We're jawing about related-party transactions now under the...

Continue Reading
Ampace Fire Test Gives Data Centers Useful Evidence

Updated Category News Views 134

Battery cabinets are becoming the awkward guest in the AI data-center boom: absolutely necessary, expensive to install, and nobody wants to discover their failure behavior during a real emergency. Ampace’s newly presented PU100 large-scale fire-test results deserve attention for that reason. This is not a magic safety stamp, and the company says the findings apply only...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring Digital Twin Advancements in Aerospace and Defense

Updated Category News Views 435

Innovations in Digital Twin Technology for Aerospace and Defense In the fast-evolving world of technology, digital twins have emerged as a transformative asset, especially in the Aerospace and Defense sectors. Recently, the Digital Twin Consortium (DTC) has published an insightful whitepaper titled Aerospace-Defense: Digital Twin Research and Technology Gap Analysis. This...

Continue Reading
Arlo Technologies to Showcase Innovations at Upcoming Conference

Updated Category News Views 126

Arlo Technologies to Present at Piper Sandler Growth Frontiers Conference Arlo Technologies, Inc. (NYSE: ARLO), a top contender in the smart home security landscape, is gearing up to showcase its latest achievements at the Piper Sandler Growth Frontiers Conference. This esteemed event highlights innovative companies leading the way in technology, and Arlo is set to make a...

Continue Reading
Plug's Innovative Trade Desk Revolutionizes EV Market Dynamics

Updated Category News Views 833

Plug's Groundbreaking Initiatives in the Electric Vehicle Sector With a substantial seed funding of $6.7 million, Plug is making significant waves in the electric vehicle (EV) market by launching its pioneering Trade Desk. This service is tailored exclusively for EVs, setting a new precedent in the automotive industry, as it allows dealerships to assess, price, and...

Continue Reading
Exciting Winter and Spring Events at Long Island Aquarium

Updated Category News Views 215

Exciting Upcoming Events at Long Island Aquarium The Long Island Aquarium is thrilled to share its lineup of engaging events for winter and spring. Visitors can expect a variety of experiences designed to entertain the whole family. Whether you're a local resident or just visiting, there's something for everyone at this spectacular underwater haven. Culinary Delights...

Continue Reading
Bakkt Holdings, Inc. Announces Third Quarter Earnings Call

Updated Category News Views 91

Bakkt Holdings, Inc. Sets Conference Call for Q3 Earnings Bakkt Holdings, Inc. (NYSE: BKKT) is making waves as it prepares to discuss its financial results for the third quarter of 2024. The company has scheduled the earnings announcement for a date soon approaching, promising insights that will interest investors and analysts alike. Details of the Earnings Call The...

Continue Reading